DRUG
Vasopressin
Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
Vasopressin for Septic Shock Pragmatic Trial
Status
Active, not recruiting
Phase
Phase 4
Enrollment
2,050
Locations
13
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.
Interventions
Treatment arms and agents.
OTHER
Recommendation to use a lower initiation threshold for vasopressin
Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
OTHER
Recommendation to use a higher initiation threshold for vasopressin
Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
Timeline
From registration to results.
First posted
Jan 22, 2024
Study start
Feb 1, 2024
Primary completion
Jul 2026
Study completion
Dec 2027
Results posted
Not reported
Registry updated
Oct 21, 2025
Outcomes
What the study measures.
Primary outcomes
28-day all-cause mortality
Time frame · 28 days
Death on or before study day 28
Secondary outcomes
Renal replacement therapy-free days to day 28
Time frame · 28 days
Number of days between day 28 and the end of the last period of renal replacement therapy prior to day 28. Death on or before day 28 will be assigned a value of -1. For patients with baseline end-stage renal failure on dialysis prior to the index hospitalization, potential values for this ordinal outcome will be 0 or -1.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥18 years 2. Admitted to a study hospital emergency department (ED) or inpatient care unit 3. Administration of vasopressor(s) for septic shock Exclusion Criteria: None
Study locations
13 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Cassia Regional Hospital
Burley, Idaho, United States
American Fork Hospital
American Fork, Utah, United States
Cedar City Hospital
Cedar City, Utah, United States
Layton Hospital
Layton, Utah, United States
Logan Regional Hospital
Logan, Utah, United States
Intermountain Medical Center
Murray, Utah, United States
McKay-Dee Hospital
Ogden, Utah, United States
Park City Hospital
Park City, Utah, United States
Utah Valley Hospital
Provo, Utah, United States
Riverton Hospital
Riverton, Utah, United States
LDS Hospital
Salt Lake City, Utah, United States
Alta View Hospital
Sandy City, Utah, United States
St. George Regional Hospital
St. George, Utah, United States
Related trials
More studies on Vasopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Mifepristone vs Misoprostol
Montefiore Medical Center · Cervical Preparation
Phase 1
Recruiting
94
2026-07
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremias · Water Intoxication
Phase 3
Completed
205
2026-07
Study of Ascending Levels of Tolvaptan in Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremia
Phase 3
Completed
243
2026-07
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.